INJ weekly report: weak momentum signals limit rally as sellers control direction
Injective (INJ) is currently trading at $4.46, having posted a marginal increase of $0.013 (+0.29%) over the past week. The asset remains subdued, positioned well below its weekly MA-20 ($4.93), MA-50 ($4.92), and MA-200 ($9.48), highlighting persistent seller pressure and a bearish long-term trend.
5.49
5.84
Highlights
- INJ is trading at $4.46, significantly below its MA-20 ($4.93), MA-50 ($4.92), and MA-200 ($9.48), confirming persistent bearish pressure across all timeframes.
- Momentum signals remain weak as MACD and ADX show a lack of bullish conviction, while negative Bull/Bear Power and neutral Stochastic RSI at 24.8 highlight continued seller control.
- Next week’s range is projected between $4.20 support and $4.82 resistance, with less than 20% probability of upside and a higher likelihood of further downside or sideways consolidation.
Bearish technical signals persist with resistance capping weekly recovery
On the weekly timeframe, INJ faces ongoing downward momentum with the price capped by a dynamic resistance at the Ichimoku Kijun level of $5.05 and anchored by local weekly support near recent lows. Weekly momentum indicators remain weak: both MACD and ADX show insufficient bullish strength, while the RSI and CCI display continued seller control without indicating deeply oversold levels. Stochastic RSI is neutral at 24.8, and Bull/Bear Power stays negative, confirming sellers' dominance throughout the week.
Sideways range likely next week amid low breakout probability
Looking ahead, INJ is expected to trade in a narrow, consolidative range between $4.20 and $4.82 over the next 5–7 trading days. Upside potential remains limited, with less than a 20% probability of a bullish breakout above $4.82 unless momentum indicators reverse decisively. The baseline scenario favors ongoing sideways action, while a drop below $4.20 would likely lead to further losses consistent with continued weekly seller pressure.
Last time, analysts noted that Injective continued to trade near the lower end of its weekly range and remained well below all major moving averages, underscoring entrenched bearish momentum. Technical indicators such as the weekly RSI, MACD, and other oscillators reflected oversold conditions, with immediate support found near recent lows and strong resistance overhead, suggesting further consolidation or downside is likely in the near term.
Latest Injective News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
